Open Access

ARTICLE

Sheng Li^*1, Guoren Zhou^*1, Wei Liu^†, Jinjun Ye^†, Fangliang Yuan^‡, Zhi Zhang^‡
Oncology Research, Vol.28, No.7-8, pp. 685-700, 2020, DOI:10.3727/096504020X15917007265498
Abstract Curcumol (Cur), isolated from the Traditional Chinese Medical plant Rhizoma Curcumae, is the bioactive component of sesquiterpene reported to possess antitumor activity. However, its bioactivity and mechanisms against lung adenocarcinoma are still unclear. We investigated its effect on lung adenocarcinoma and elucidated its underlying molecular mechanisms. In vitro, Cur effectively suppressed proliferation, migration, and invasion of lung adenocarcinoma cells A549 and H460, which were associated with the altered expressions of signaling molecules, including p-AKT, p-PI3K, p-LRP5/6, AXIN, APC, GSK3 and p- -catenin, matrix metalloproteinase (MMP)-2, and MMP-9. Furthermore, Cur significantly induced cell apoptosis of A549 and H460 by promoting the… More >

View

563

Download

428

Open Access

ARTICLE

Ching-Wen Huang^*, Cheng-Jen Ma^*†, Wei-Chih Su^*, Yi-Ting Chen^‡§, Hsiang-Lin Tsai^*¶, Yung-Sung Yeh^*#, Tsung-Kun Chang^*, Wen-Hung Hsu^**††, Fang-Jung Yu^**††, Jaw-Yuan Wang^{*¶‡‡§§¶¶##}
Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822
Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through… More >

View

541

Download

361

Open Access

ARTICLE

Pihua Han^*†1, Haiming Yang^‡1, Xiang Li^*1, Jie Wu^*, Peili Wang^§, Dapeng Liu^*, Guodong Xiao^¶, Xin Sun^*, Hong Ren^*
Oncology Research, Vol.28, No.7-8, pp. 715-729, 2020, DOI:10.3727/096504020X16037124605559
Abstract The aim of this study was to identify a novel cancer stemness-related ceRNA regulatory axis in lung adenocarcinoma (LUAD) via weighted gene coexpression network analysis of a stemness index. The RNA sequencing expression profiles of 513 cancer samples and 60 normal samples were obtained from the TCGA database. Differentially expressed mRNAs (DEmRNAs), lncRNAs (DElncRNAs), and miRNAs (DEmiRNAs) were identified with R software. Functional enrichment analysis was conducted using DAVID 6.8. The ceRNA network was constructed via multiple bioinformatics analyses, and the correlations between possible ceRNAs and prognosis were analyzed using Kaplan–Meier plots. WGCNA was then applied to distinguish key genes… More >

View

538

Download

438

Open Access

ARTICLE

Huiling Wang^*, Xin Hu^†, Feng Yang^‡, Hui Xiao^*
Oncology Research, Vol.28, No.7-8, pp. 731-744, 2020, DOI:10.3727/096504020X16100888208039
Abstract This study was designed to investigate the precise mechanisms of miR-325-3p/S100A2 axis in breast cancer (BC). In this study, we found that the level of miR-325-3p was dramatically increased in BC tissues and cell lines, and the expression of S100A2 was significantly decreased. Also, the high level of miR-325-3p was closely associated with low expression of S100A2 in BC tissues. Moreover, introduction of miR-325-3p significantly promoted proliferation, invasion, and EMT of BC cells. Bioinformatics analysis predicted that the S100A2 was a potential target gene of miR-325-3p. Luciferase reporter assay demonstrated that miR-325-3p could directly target S100A2. In addition, miR-325-3p overexpression… More >

View

524

Download

433

Open Access

ARTICLE

Huan Ma¹, Cong Nie¹, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai, Yuxiang Mao, Qian Sun, Rong Lu
Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507
Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by ON-01910.Na was tumor specific and dose dependent in retinoblastoma cells,… More >

View

586

Download

364

Open Access

ARTICLE

Hongde Li^*†‡, Yueshuo Li^*†‡, Jianmin Hu^*†‡, Sufang Liu^§, Xiangjian Luo^*†‡¶, Min Tang^*†‡, Ann M. Bode^#, Zigang Dong^#**, Xinqi Liu^††, Weihua Liao^‡‡, Ya Cao^{*†‡¶ §§¶¶}
Oncology Research, Vol.28, No.7-8, pp. 763-778, 2020, DOI:10.3727/096504021X16135618512563
Abstract Epstein–Barr virus (EBV)-encoded latent membrane protein 1 (LMP1) plays an important oncogenic role in the viral latent infection. Recently, increasing evidence indicates that the high expression of LMP1 during EBV lytic cycle is related to the viral lytic replication. However, the mechanism by which LMP1 regulates EBV lytic replication remains unclear. (−)-Epigallocatechin-3-gallate (EGCG) prevents carcinogenesis by directly targeting numerous membrane proteins and effectively inhibits EBV lytic cascade. Here, we demonstrated that LMP1 promotes EBV lytic replication through the downstream signal molecules MAPKs, including ERKs, p38, and JNKs. LMP1 induces the phosphorylation of p53 through MAPKs to enhance the ability of… More >

View

541

Download

393

Open Access

ARTICLE

Sarah A. Scuderi^*, Marika Lanza^*, Giovanna Casili^*, Francesca Esposito^†, Cristina Colarossi^‡, Dario Giuffrida^‡, Paterniti Irene^*, Salvatore Cuzzocrea^*,* Emanuela Esposito^*, Michela Campolo^*
Oncology Research, Vol.28, No.7-8, pp. 779-790, 2020, DOI:10.3727/096504021X16161478258040
Abstract Glioma are common malignant brain tumors, among which glioblastoma multiforme (GBM) has the worst prognosis. Different studies of GBM revealed that targeting nuclear factor B (NF- B) induced an attenuation tumor proliferation and prolonged cell survival. TBK1 {TANK [TRAF (TNF (tumor-necrosis-factor) receptorassociated factor)-associated NF- B activator]-binding kinase 1} is a serine/threonine protein kinase, and it is a member of the I B kinase (IKK) family involved in NF- B pathway activation. The aim of this study was to investigate the potential effect of BX795, an inhibitor of TBK1, in an in vitro and ex vivo model of GBM. GBM cell… More >

View

505

Download

339

Open Access

ARTICLE

Chunmou Li^*1, Xiaomin Peng^*1, Chuchu Feng^*1, Xilin Xiong^*, Jianxin Li^†, Ning Liao^‡, Zhen Yang^§, Aiguo Liu^¶, Pingping Wu^*, Xuehong Liang^†, Yunyan He^‡, Xin Tian^§, Yunbi Lin^§, Songmi Wang^¶, Yang Li^*
Oncology Research, Vol.28, No.7-8, pp. 791-800, 2020, DOI:10.3727/096504021X16184815905096
Abstract This nonrandomized, multicenter cohort, open-label clinical trial evaluated the efficacy and safety of combined chemotherapy with arsenic trioxide (ATO) in children with stage 4/M neuroblastoma (NB). We enrolled patients who were newly diagnosed with NB and assessed as stage 4/M and received either traditional chemotherapy or ATO combined with chemotherapy according to their own wishes. Twenty-two patients were enrolled in the trial group (ATO combined with chemotherapy), and 13 patients were enrolled in the control group (traditional chemotherapy). Objective response rate (ORR) at 4 weeks after completing induction chemotherapy was defined as the main outcome, and adverse events were monitored… More >

View

538

Download

381

Open Access

ARTICLE

Tsung-Kun Chang^*†, Tzu-Chieh Yin^‡§, Wei-Chih Su^*†, Hsiang-Lin Tsai^*¶, Ching-Wen Huang^*¶, Yen-Cheng Chen^*, Ching-Chun Li^*, Po-Jung Chen^*, Cheng-Jen Ma^*§, Kuo-Hsiang Chuang^#, Tian-Lu Cheng^**, Jaw-Yuan Wang^{*†¶††‡‡§§}
Oncology Research, Vol.28, No.7-8, pp. 801-809, 2020, DOI:10.3727/096504021X16218531628569
Abstract Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients. Diarrhea is the most common adverse event (AE). The underlying mechanism of irinotecaninduced diarrhea is intestinal mucosal damage caused by SN-38 (active metabolite of irinotecan) hydrolyzed from SN-38G (inactive metabolite) by bacterial -glucuronidase ( G). According to an animal study, silymarin reduces the activity of bacterial G without impairing antitumor efficacy. We conducted a prospective openlabel pilot study to evaluate the effect of silymarin as supplementation in reducing toxicities of mCRC patients undergoing irinotecan-based chemotherapy. We enrolled and randomized 70 mCRC patients receiving first-line… More >

View

550

Download

380

Open Access

BRIEF COMMUNICATION

Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis
Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750
Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two patients received hypomethylating agents with… More >

View

605

Download

320

Open Access

ERRATUM

Weichen Hou^*, Lei Song^†, Yang Zhao^*, Qun Liu^*, Shuyan Zhang^‡
Oncology Research, Vol.28, No.7-8, pp. 815-818, 2020, DOI:10.3727/096504021X16240202939988
Abstract The role of miRNAs in the radiosensitivity of glioma cells and the underlying mechanism is still far from clear. In the present study, we detected six downregulated and seven upregulated miRNAs in the serum after radiotherapy compared with paired serum samples before radiotherapy via miRNA panel PCR. Among these, miR-17-5p was highly reduced (fold change = −4.21). Further, we validated the levels of miR-17-5p in all serum samples with qRT-PCR. In addition, statistical analysis suggested that a reduced miR-17-5P level was positively associated with advanced clinical stage of glioma, incidence of relapse, and tumor differentiation. Moreover, we provided evidence that… More >

View

519

Download

368

Open Access

ERRATUM

Chang Li^*, Xiaoping Li^†, Shuohui Gao^*, Chang Li^‡, Lianjun Ma^§
Oncology Research, Vol.28, No.7-8, pp. 819-822, 2020, DOI:10.3727/096504021X16240202940003
Abstract Gastric cancer is the fourth most common type of cancer and the second highest leading cause of cancer-related deaths worldwide. It has already been established that miR-133a is involved in gastric cancer. In this study, we investigated the molecular mechanisms by which miR-133a inhibits the proliferation of gastric cancer cells. We analyzed the proliferative capacity of human gastric cancer cells SNU-1 using an MTT assay. Cell apoptosis was determined using flow cytometry. The expression levels of ERBB2, p-ERK1/2, and p-AKT in SNU-1 cells were determined using Western blot analysis. To confirm that ERBB2 is a direct target of miR-133a, a… More >

View

511

Download

351

Open Access

ERRATUM

Yanli Wang^*, Jia Li^†, Chunling Xu^†, Xiaomeng Zhang^†
Oncology Research, Vol.28, No.7-8, pp. 823-825, 2020, DOI:10.3727/096504021X16240202940021
Abstract Increasing evidence indicates that the dysregulation of microRNAs is associated with the development and progression of various cancers. MicroRNA-139-5p (miR-139-5p) has been reported to have a tumor suppressive role in many types of cancers. The role of miR-139-5p in ovarian cancer (OC) is poorly understood. The purpose of the present study was to explore the expression of miR-139-5p and its function in OC. The results showed that miR-139-5p expression was markedly downregulated in OC tissues and cell lines. In addition, underexpression of miR-139-5p was significantly associated with FIGO stage, lymph mode metastasis, and poor overall survival of OC patients. Functional… More >

View

484

Download

345

Open Access

ERRATUM

Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1,Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*
Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409
Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration,… More >

View

524

Download

367

Open Access

RETRACTION

Wenliang Liu^*, Peng Xiao^†, Han Wu^*, Li Wang^*, Demiao Kong^*, Fenglei Yu^*
Oncology Research, Vol.28, No.7-8, pp. 829-829, 2020, DOI:10.3727/096504021X16207253542097
Abstract This article has no abstract. More >

View

427

Download

349

Open Access

RETRACTION

Zhili Cao^*1, Xiang Zheng^†1, Lei Cao^*, Naixin Liang^*
Oncology Research, Vol.28, No.7-8, pp. 831-831, 2020, DOI:10.3727/096504020X16231418632584
Abstract This article has no abstract. More >

View

496

Download

297

Open Access

RETRACTION

Chao Jiang^*, Xueyan Liu^†, Meng Wang^*, Guoyue Lv^*, Guangyi Wang^*
Oncology Research, Vol.28, No.7-8, pp. 833-833, 2020, DOI:10.3727/096504018X16233193839045
Abstract This article has no abstract. More >

View

518

Download

357

Open Access

RETRACTION

Lili Lv^*, Xiaodong Wang^†
Oncology Research, Vol.28, No.7-8, pp. 835-835, 2020
Abstract This article has no abstract. More >

View

465

Download

346